MNOV Stock Medicinova (MNOV, $1.46) RSI Indicator left the overbought zone on July 25, 2025

GET DAILY SIGNALS

Get AI intraday signals

MNOV - Medicinova

RSI signal

View

Odds of DOWN Trend

Price: $1.46

Daily change: +$0.22 (+17.74%)

Daily volume: 198.2K

Capitalization: $71.6M

Industry: Biotechnology

MNOV in -4.69% downward trend, sliding for three consecutive days on July 16, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MNOV declined for three days, in of 311 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 22, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MNOV as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for MNOV entered a downward trend on July 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where MNOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on July 21, 2025. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.434) is normal, around the industry mean (18.664). P/E Ratio (0.000) is within average values for comparable stocks, (59.851). MNOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.578). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (98.039) is also within normal values, averaging (279.346).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MNOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.